CA3214400A1 - Nouveaux (homo) piperidinyl heterocycles utilises en tant que ligands sigma - Google Patents

Nouveaux (homo) piperidinyl heterocycles utilises en tant que ligands sigma Download PDF

Info

Publication number
CA3214400A1
CA3214400A1 CA3214400A CA3214400A CA3214400A1 CA 3214400 A1 CA3214400 A1 CA 3214400A1 CA 3214400 A CA3214400 A CA 3214400A CA 3214400 A CA3214400 A CA 3214400A CA 3214400 A1 CA3214400 A1 CA 3214400A1
Authority
CA
Canada
Prior art keywords
compound
piperidin
methylisoxazol
formula
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3214400A
Other languages
English (en)
Inventor
Jose Luis Diaz-Fernandez
Carmen ALMANSA-ROSALES
Ute Christmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leitat Technological Centre
Original Assignee
Leitat Technological Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leitat Technological Centre filed Critical Leitat Technological Centre
Publication of CA3214400A1 publication Critical patent/CA3214400A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouveaux composés de formule (I) en tant que ligands sigma ayant une grande affinité pour les récepteurs sigma, le récepteur sigma-1 ((?1) et/ou le récepteur sigma-2 (?2). La présente invention concerne également le procédé de préparation de ceux-ci, des compositions les comprenant, et leur utilisation en tant que médicaments.
CA3214400A 2021-04-07 2022-04-06 Nouveaux (homo) piperidinyl heterocycles utilises en tant que ligands sigma Pending CA3214400A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382291 2021-04-07
EP21382291.9 2021-04-07
PCT/EP2022/059085 WO2022214531A1 (fr) 2021-04-07 2022-04-06 Nouveaux (homo) pipéridinyl hétérocycles utilisés en tant que ligands sigma

Publications (1)

Publication Number Publication Date
CA3214400A1 true CA3214400A1 (fr) 2022-10-13

Family

ID=75529946

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3214400A Pending CA3214400A1 (fr) 2021-04-07 2022-04-06 Nouveaux (homo) piperidinyl heterocycles utilises en tant que ligands sigma

Country Status (13)

Country Link
US (1) US20240217959A1 (fr)
EP (1) EP4320123A1 (fr)
JP (1) JP2024513117A (fr)
KR (1) KR20240017785A (fr)
CN (1) CN117460729A (fr)
AR (1) AR125299A1 (fr)
AU (1) AU2022252951A1 (fr)
BR (1) BR112023020843A2 (fr)
CA (1) CA3214400A1 (fr)
IL (1) IL307569A (fr)
MX (1) MX2023011884A (fr)
TW (1) TW202304448A (fr)
WO (1) WO2022214531A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024105225A1 (fr) 2022-11-18 2024-05-23 Universitat De Barcelona Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083595B1 (fr) * 2013-12-20 2020-05-27 Esteve Pharmaceuticals, S.A. Composés de pipéridine ayant une activité multimodale contre la douleur
US9981942B2 (en) * 2013-12-20 2018-05-29 Laboratorios Del Dr. Esteve S.A. Piperidine derivatives having multimodal activity against pain

Also Published As

Publication number Publication date
WO2022214531A1 (fr) 2022-10-13
EP4320123A1 (fr) 2024-02-14
MX2023011884A (es) 2023-10-17
CN117460729A (zh) 2024-01-26
AR125299A1 (es) 2023-07-05
KR20240017785A (ko) 2024-02-08
IL307569A (en) 2023-12-01
US20240217959A1 (en) 2024-07-04
TW202304448A (zh) 2023-02-01
JP2024513117A (ja) 2024-03-21
BR112023020843A2 (pt) 2023-12-12
AU2022252951A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
WO2022229405A1 (fr) Dérivés de pyridine-sulfonamide utilisés en tant que ligands sigma
CA3211638A1 (fr) Nouveaux derives de 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine utiles en tant que ligands sigma
JP2018533598A (ja) 薬物乱用の治療および薬物中毒の治療のためのオキサ−アザスピロ化合物
CA3214400A1 (fr) Nouveaux (homo) piperidinyl heterocycles utilises en tant que ligands sigma
WO2022223554A1 (fr) Dérivés de 1h-pyrazole utilisés en tant que ligands sigma
AU2022256725A1 (en) NEW PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS SIGMA LIGANDS
WO2022195022A1 (fr) Nouveaux dérivés de 5,6,7,8-tétrahydropyrido[4', 3': 4,5]thiéno[2,3-d]pyrimidin-4(3h)-one utilisés en tant que ligands sigma
CA3119882A1 (fr) Composes spiro heterocycliques constituant des inhibiteurs du recepteur de l'am2
KR20180073638A (ko) 통증에 대해 활성을 갖는 옥사-디아자스피로 화합물들
JP2018531263A6 (ja) 疼痛に対して活性を有するオキサジアザスピロ化合物
JP6337092B2 (ja) 三環式トリアゾール系化合物